HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hendry, P. J. Articles by Keon, W. J. Search for Related Content PubMed PubMed Citation Articles by Hendry, P. J. Articles by Keon, W. J. Related Collections Mechanical Circulatory Assistance

Ann Thorac Surg 2001;71:S166-S170
© 2001 The Society of Thoracic Surgeons

---

Session 4: pulsatile implantable devices

The HeartSaver left ventricular assist device: an update

^a Division of Cardiac Surgery, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
^b Division of Cardiac Anesthesia, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
^c Division of Cardiovascular Devices, University of Ottawa Heart Institute, Ottawa, Ontario, Canada

Address reprint requests to Dr Hendry, Division of Cardiac Surgery, Ottawa Heart Institute, Room H207, 40 Ruskin St, Ottawa, ON K1Y 4W7, Canada

Presented at the Fifth International Conference on Circulatory Support Devices for Severe Cardiac Failure, New York, NY, Sept 15–17, 2000.

Abstract

Background. Ventricular assist devices have been shown to be effective as bridges to transplantation and recovery for patients with end-stage heart failure. Current technology has been limited because of the need for percutaneous connections with controllers. The HeartSaver ventricular assist device (VAD) (World Heart Corporation, Ottawa, Ontario, Canada) was developed with the intention of having a completely implantable, portable VAD system. The system consists of an electrohydraulic blood pump, internal and external battery power, and a transcutaneous energy transfer and telemetry unit that allows for power transmission through the skin. Control of the device may be achieved locally or remotely through a variety of communication systems.

Methods. The device has been modified with the Series II preclinical version being available for in vitro (mock loop) and in vivo (bovine model) testing.

Results. Seventeen Series II devices have been functional on mock loops or other testing trials for an accumulated 900 days of operation. There have been eight acute experiments using a bovine model to test various components as they have become available from manufacturing. Mean pump output was 10.4 ± 1.1 L/min in full-fill/full-eject mode. Changes in the last 24 months include (1) cannula redesign for better port alignment and integration of tissue valves; (2) battery redesign to convert to new lithium-ion cells; (3) optimized infrared information and electromagnetic inductance energy transmission through various skin thicknesses and pigmentation; and (4) improved reliability of internal and external controller hardware and software.

Conclusions. Modifications have been required to optimize the HeartSaver VAD’s performance. The final HeartSaver VAD design will be produced in the near future to allow for formal in vitro and in vivo testing before clinical implantation.

This article has been cited by other articles:

				M. Haddad, R. G. Masters, P. J. Hendry, A. Kawai, J. P. Veinot, G. Lavallee, and T. V. Mussivand Intercontinental LVAS Patient Transport Ann. Thorac. Surg., November 1, 2004; 78(5): 1818 - 1820. [Abstract] [Full Text] [PDF]

				E. L. Kukuy, M. C. Oz, and Y. Naka Long-Term Mechanical Circulatory Support Card. Surg. Adult, January 1, 2003; 2(2003): 1491 - 1506. [Full Text]